Q4 2024 Cellectis SA Earnings Call Transcript
Key Points
- Cellectis SA (CLLS) announced the start of three new research and development programs in collaboration with AstraZeneca, including allogenic CAR T therapies for hematological malignancies and solid tumors, as well as in vivo gene therapy for genetic disorders.
- AstraZeneca completed an additional equity investment of $140 million in Cellectis SA (CLLS), increasing its ownership to approximately 44% of the share capital.
- Cellectis SA (CLLS) secured a EUR40 million credit facility from the European Investment Bank, ensuring a cash runway to fund operations into mid-2027.
- The FDA granted orphan drug designation to Cellectis SA (CLLS)'s product candidate UCART22 for the treatment of relapsed or refractory acute lymphoblastic leukemia.
- Cellectis SA (CLLS) showcased promising CAR T strategies utilizing TALEN gene editing technology, with data presented at major conferences and published in scientific journals.
- Cellectis SA (CLLS) faces risks and uncertainties that may cause actual results to differ from forecasts, as highlighted in their SEC filings.
- The company is still in the early stages of clinical trials, with Phase 1 data for UCART22 and UCART20x22 expected only in late 2025.
- Cellectis SA (CLLS) has ongoing legal matters, such as the arbitration with Sevier, which could impact future operations.
- The competitive landscape for CAR T therapies is challenging, with recent discontinuations in the field highlighting potential hurdles.
- Cellectis SA (CLLS) has a significant cash burn, with a net cash burn of $60 million in 2024, despite revenue from partnerships.
Good day, everyone, and welcome to today's Cellectis this full-year 2024 earnings conference call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-answer session. (Operator Instructions) Please note today's conference is being recorded. I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Arthur Stril. Please go ahead.
Good morning, and welcome everyone to Cellectis fourth quarter and full-year 2024 business update and financial results conference call. Joining me on the call today are Doctor Andre Choulika, our Chief Executive Officer; and Doctor Adrian Kilcoyne, our Chief Medical Officer.
Yesterday evening, Cellectis issued a [6K-M] press release reporting our financial statements for the 12-month period ended December 30 2024 and a business update. The reports and press release are available on our website at cellectis.com.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
